Avatar

Clinical Trials in Myeloma in 2018

By Krina Patel 4 Videos
06/2018
0 Comments
Login to view comments. Click here to Login

Featured Video

10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya

Featured Video

10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya

Related Content

AUTOPLAY
UChicago Medicine Comprehensive Cancer Center

CAR T-Cell Symposium 2019

Fri, Sep 27, 2019
Yale Cancer Center

Immuno-Oncology Symposium

Fri, Oct 11, 2019
Eurasian Hematology-Oncology Group

Xth Eurasian Hematology-Oncology Congress

Tue, Oct 8, 2019
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
13:23
Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
07:23
Indy Hematology Review

Novel Immune Therapies in Myeloma: BCMA Immunotoxin, Bites, and CAR T cells

Feat. K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
09:49
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

16:22
Society of Hematologic Oncology Sixth Annual Meeting

FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study

Feat. S. Jagannath
10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya
15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma

12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:47
Society of Hematologic Oncology Sixth Annual Meeting

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
09:01
Maria-Victoria Mateos

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

15:31
Parameswaran Hari

Refractory and Relapsing Myeloma - When to Treat and Options Available

13:30
Helen Heslop

CAR T-cell Therapy for Hematologic Malignancies Other Than CD19

14:43
Society of Hematologic Oncology Sixth Annual Meeting

What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?

Feat. R. Orlowski
09:46
2018 Pan Pacific Lymphoma Conference

CAR T-cell Toxicities and Team Management

Feat. S. Blumel
10:38
Krina Patel

How Do We Make Responses Durable in Multiple Myeloma?